Review Article
An Overview of Systematic Reviews of Using Chinese Medicine to Treat Polycystic Ovary Syndrome
Table 10
GRADE quality-of-evidence ratings for luteinizing hormone/follicle-stimulating hormone level.
| Included systematic reviews | Number of studies included | Luteinizing hormone/follicle-stimulating hormone effect (95% CI) | GRADE quality of evidence | Relegation factors |
| Xiao Chao 2016 [18] | 4 | MD = –0.81, 95% CI (–1.17, –0.45) | Very low | ①②④⑤ | Lu RuLing et al. 2018 [20] | 12 | MD = –0.25, 95% CI (–0.44, –0.06) | Very low | ①②⑤ | Ji Lin 2019 [26] | 11 | SMD = –0.45, 95% CI (–0.68, –0.23) | Low | ①② | Xie Peng Peng et al. 2019 [27] | 3 | WMD = –1.04, 95% CI (–1.78, –0.33) | Very low | ①②④⑤ | Dong YuFang 2020 [29] | 22 | SMD = –0.39, 95% CI (–0.60, –0.19) | Very low | ①②④ | Lin BeiBei 2020 [32] | 14 | MD = –0.37, 95% CI (–0.53, –0.21) | Very low | ①②④ |
|
|
Note. CI: confidence interval; MD: mean difference; SMD: standardized mean difference; WMD: weighted mean difference; ①: limitation; ②: inconsistency; ③: indirectness; ④: publication bias; ⑤: imprecision.
|